Sernova accelerates its first-to-market strategy
Sernova Corp. is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells. Examples of this are human donor cells, corrected human cells and stem cell-derived cells. This is to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia. It’s also for other diseases treated through replacement of proteins or hormones missing or in short supply within the body.
Moreover, Sernova has multibillion-dollar market potential for each of its clinical indications. The Company is developing a functional cure for diabetes. They also have early promising clinical safety and effectiveness for its novel therapeutic approach.
Sernova’s regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch™, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body and for which patients must take injections on a regular basis.
Sernova is developing technologies to treat diseases such as diabetes in which insulin and related factors are missing from the body that finely control blood sugar levels. Hemophilia, a bleeding disease in which a clotting factor, Factor VIII is missing from the body. This results in uncontrolled bleeding episodes and thyroid disease. Thyroid disease is where patients lack the ability to produce needed thyroid hormones which are important in controlling metabolism and other functions, are also indications in Sernova’s therapeutic pipeline.
By developing cells that replace these proteins, hormones or factors and deliver them to the body as required, Sernova’s platform technologies have the ability to treat a multitude of diseases. Further, they hope to significantly improve the quality of life of subjects with chronic diseases and improve therapeutic outcomes.
Sernova is committed to the development and clinical advancement of its regenerative medicine therapeutics technologies for chronic diseases.
For more information on Sernova Corp. (TSX.V: SVA, OTCQB: SEOVF) please fill out the form below.